Pioglitazone use is associated with reduced risk of Parkinson’s disease in patients with diabetes: A systematic review and meta-analysis
Liudan Chen, Yangu Tao, Jianjun Li, Mengru Kang
Abstract
OBJECTIVE: This meta-analysis aimed to evaluate the effect of pioglitazone on Parkinson's disease (PD) in diabetes patients. METHODS: tests were used to assess statistical heterogeneity. A dose-response meta-analysis was conducted using the least squares trend estimation method. RESULTS: Three studies were eligible for this meta-analysis. Compared with diabetes patients who did not use pioglitazone, there was a significant reduction in the risk of PD (RR of 0.87 [95 % CI 0.62-0.99, P = 0.039]) in pioglitazone users. No significant difference in PD risk was noted in diabetes patients taking 438 dose-duration-days (DDDs) of pioglitazone or lower compared with those who did not. When the DDD of pioglitazone was 438, the RR was 0.85 (95 % CI [0.72-1.00], P = 0.05). When the DDD of pioglitazone was > 438, the risk of PD in patients with diabetes was significantly decreased (P < 0.05) and showed an approximate linear correlation trend. CONCLUSION: Pioglitazone administration in PD in diabetes patients is significantly associated with a decrease in the risk of PD.